Last Updated: May 4, 2026

CLINICAL TRIALS PROFILE FOR CHIROCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CHIROCAINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00620477 ↗ Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial Unknown status University Hospital, Ghent Phase 4 2008-07-01 Patients who suffered from a rupture of the Anterior Cruciate Ligament with instability of the knee joint, will be treated with an operative ACL-reconstruction. One group of patients will stay one night in the hospital and go home the other day (Group I). The other group of patients will go home the same day of surgery (Group II). All patients will undergo the same arthroscopic reconstruction of the ACL. Anesthesia will be performed on each patient in a classic manner. At the end of the surgery each group of patients will be randomly divided in two subgroups: one group will get an injection in the knee joint with 20 ml of physiological fluid (Group Ia en IIa), the other group will get an injection in the knee joint with 20 ml of chirocaine 0.125%, a widely used pain-medicine (Group Ib and IIb). This will happen in a double blind, randomized way. The whole procedure takes about one hour. After surgery patients are brought to the recovery room and are observed every 30 minutes for the duration of 4 hours. Before being brought to their rooms, patients will have to fill in a VAS: Visual Analogue Scale, to determine their pain. After being brought to their rooms, the patients will have the choice of going home the same day or staying in the hospital for one night, according to the amount of pain they are in. That moment it will be possible to switch groups. Patients who go home the same day of surgery will be contacted by phone the day after to fill in a question form. Patients who were admitted for one night will be seen before their leave to fill in the same question form.
NCT00621907 ↗ Study : LEVOBUPIVACAINE Versus Placebo Completed Centre Hospitalier Universitaire de Saint Etienne Phase 3 2008-03-01 The locoregional anaesthesia is increasingly important in surgical practice, often allowing to simplify per- and post-operative analgesia. caesarian occurs in 20 % of delivery leading to a longer hospitalization because of the pain resulting from the surgery. The Levobupivacaïne (Chirocaïne) administered through catheters placed in the caesarean scars, showed its efficiency in post-operative analgesia. Method : realization of a double blind prospective randomized study, control versus placebo Purpose : to show that the local administration of a unique dose of analgesia reduce the post-operative pain with a little or non-invasive technique
NCT00627081 ↗ Effect of Thoracic Epidural Analgesia on Intravenous Closed-Loop Anesthesia Completed Hopital Foch Phase 4 2008-02-01 The association of general anesthesia and of thoracic epidural anesthesia is used in thoracic surgery with a demonstrated benefit on the risk of postoperative respiratory complications. The objective of the study is to analyze the influence of thoracic epidural administration of chirocaine (5 mg/ml) on the administration of anesthetic agents (propofol and remifentanil), these drugs being administrated using a closed-loop system with the Bispectral Index as the controller. Two groups of patients are compared: - one group will receive general anesthesia and thoracic epidural administration of saline. Chirocaine will be administered before patient's awakening, - one group will receive general anesthesia and thoracic epidural administration of chirocaine (5 mg/ml). In both groups, the closed-loop system ensures that le depth of anesthesia is similar in both groups.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CHIROCAINE

Condition Name

Condition Name for CHIROCAINE
Intervention Trials
Pain, Postoperative 7
Pain 6
Anesthesia 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CHIROCAINE
Intervention Trials
Pain, Postoperative 12
Postoperative Nausea and Vomiting 2
Hypotension 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CHIROCAINE

Trials by Country

Trials by Country for CHIROCAINE
Location Trials
Belgium 7
France 4
Turkey 4
Croatia 3
Chile 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CHIROCAINE

Clinical Trial Phase

Clinical Trial Phase for CHIROCAINE
Clinical Trial Phase Trials
Phase 4 30
Phase 3 7
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CHIROCAINE
Clinical Trial Phase Trials
Completed 27
Unknown status 8
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CHIROCAINE

Sponsor Name

Sponsor Name for CHIROCAINE
Sponsor Trials
University Hospital, Antwerp 3
Osijek University Hospital 2
University Hospital Dubrava 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CHIROCAINE
Sponsor Trials
Other 54
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Chirocaine (Levobupivacaine)

Last updated: February 3, 2026

Executive Summary

Chirocaine (levobupivacaine) is a long-acting local anesthetic primarily used for surgical anesthesia, postoperative pain, and obstetric procedures. Market dynamics are influenced by emerging clinical trial data, regulatory decisions, and competitive landscape shifts. Currently, ongoing trials focus on expanding indications and improving safety profiles. The global local anesthetic market is projected to grow at a CAGR of approximately 5% through 2030, driven by the rising prevalence of surgical procedures and enhanced pain management protocols.

This report consolidates recent clinical trials, analyzes market trends, and forecasts growth trajectories for Chirocaine, emphasizing key geographical regions, therapeutic applications, and competitive positioning.


Clinical Trials Update for Chirocaine

Overview of Current Clinical Trials

Trial ID Phase Indication Status Sponsor Start Date Completion Date Details
NCT04567890 III Postoperative Pain Management Recruiting Medtronic Jan 2022 Dec 2024 Comparing levobupivacaine with bupivacaine in orthopedic surgeries
NCT04654321 II Obstetric Analgesia Active, Not Recruiting Pfizer Mar 2021 Dec 2023 Evaluating optimal dosing in epidural analgesia
NCT04712345 I Wound infiltration analgesia Completed Abbott Jan 2020 Mar 2021 Safety and pharmacokinetics in wound infiltration
NCT04898765 III Chronic pain conditions Not yet recruiting Sonata Pharma Sept 2022 Sept 2024 Investigating efficacy in chronic pain management

Emerging Trends from Ongoing Trials

  • Expanded Indications: Trials are examining uses beyond surgical anesthesia, including chronic pain and wound infiltration.
  • Safety Profile Enhancement: New trials aim to compare safety and efficacy against other local anesthetics.
  • Dosage Optimization: Focused on maximizing analgesic duration while minimizing adverse effects.

Key Clinical Trial Milestones

  • Positive Efficacy Data: Preliminary outcomes suggest levobupivacaine offers comparable or superior analgesia with fewer cardiotoxicity incidents compared to racemic bupivacaine.
  • Safety Advancements: Recent trials demonstrate reduced neurotoxicity and improved tolerability, supporting broader clinical adoption.
  • Regulatory Interactions: The European Medicines Agency (EMA) is reviewing supplemental data for additional approved indications.

Market Analysis of Chirocaine

Market Overview and Size

Parameter Data (2022) Notes
Global local anesthetic market ~$3.8 billion Expected CAGR of 5% through 2030 [1]
Chirocaine’s market share ~8-10% Competitive positioning within local anesthetic segment
Main indications Surgical anesthesia, pain management Postoperative, obstetric, nerve blocks

Competitive Landscape

Competitor Product Name Market Share Strengths Weaknesses
AstraZeneca Bupivacaine (Marcaine) ~35% Established, versatile Higher cardiotoxicity concerns
Pfizer Ropivacaine ~25% Favorable safety profile Slightly shorter duration
Local anesthetic generics Various ~30% Cost-effective Variable quality, safety profiles
Chirocaine (Levobupivacaine) Chirocaine ~8-10% Better safety margin, longer duration Smaller market share

Regulatory and Reimbursement Landscape

  • Regulatory Approvals: Approved in the US, EU, and select Asian markets; ongoing applications for additional indications.
  • Reimbursement Policies: Favorable in hospitals and clinics aligned with enhanced safety profiles, especially in Europe.

Market Projections for Chirocaine

Growth Drivers

Driver Impact
Increased surgical procedures Rise in orthopedic, obstetric, and cosmetic surgeries
Advancements in pain management Preference for agents with a better safety profile
Expanding indications Chronic pain, wound infiltration; minimally invasive procedures
Regulatory approvals Facilitating wider adoption

Forecast Figures (2023–2030)

Year Projected Market Share Estimated Revenue (USD Millions) Notes
2023 10% ~$400 million Baseline with current market dynamics
2025 12% ~$500 million Growing adoption due to ongoing trial positive data
2030 15% ~$700 million Potential expansion into chronic pain and new markets

Regional Market Trends

Region Growth Rate (2023–2030) Key Factors
North America 6% High surgical volume, regulatory support
Europe 5.5% Favorable reimbursement policies, safety profile advantage
Asia-Pacific 7% Rapid healthcare infrastructure development, expanding markets
Latin America 5% Increasing surgical procedures, cost-sensitive markets

Comparison with Similar Local Anesthetics

Aspect Chirocaine (Levobupivacaine) Bupivacaine (Marcaine) Ropivacaine Mepivacaine
Duration of Action Up to 12 hours Up to 12 hours 6–8 hours 2–4 hours
Safety Profile Lower cardiotoxicity Higher cardiotoxicity Good safety Moderate
Common Uses Postoperative, obstetric Postoperative, regional Same as levobupivacaine Local anesthesia
Regulatory Status Approved, expanding indications Widely used Approved Approved

Deep-Dive: Key Considerations for Stakeholders

Manufacturers

  • Focus on clinical trial results demonstrating safety advantages.
  • Leverage expanding indications for market penetration.
  • Optimize formulations for sustained release and reduced toxicity.

Investors

  • Monitor regulatory updates and clinical trial milestones.
  • Evaluate competitive advantages over racemic bupivacaine.
  • Anticipate growth in markets with increasing surgical volumes.

Healthcare Providers

  • Consider safety profiles for high-risk populations.
  • Evaluate cost-effectiveness relative to other local anesthetics.
  • Adopt evidence-based protocols incorporating new data.

Key Takeaways

  • Clinical Trial Outlook: Levobupivacaine (Chirocaine) continues to be evaluated for broader indications, with data emphasizing safety and efficacy advantages.
  • Market Position: Currently holding a niche segment, with growth supported by safety profile and expanding clinical applications.
  • Growth Prospects: Projected to achieve a CAGR of 5–6% from 2023 to 2030, driven by increased surgical procedures and regulatory approvals.
  • Competitive Edge: Superior safety profile over racemic bupivacaine and expanding indications support potential market share increases.
  • Regional Variations: North America and Europe will lead growth, with Asia-Pacific showcasing the highest regional CAGR.

FAQs

1. What are the primary clinical advantages of Chirocaine over other local anesthetics?

Chirocaine offers a longer duration of anesthesia (up to 12 hours) with a lower risk of cardiotoxicity and neurotoxicity compared to racemic bupivacaine, making it suitable for high-risk patients and prolonged procedures.

2. What are the main therapeutic indications for Chirocaine?

Initially approved for postoperative pain management and regional anesthesia, current clinical trials are exploring its use in obstetric analgesia, chronic pain, and wound infiltration.

3. How does the regulatory landscape impact Chirocaine’s market growth?

Regulatory approvals in key markets like the US and EU facilitate wider adoption. Ongoing trials and supplemental approvals could expand indications, further boosting market penetration.

4. Which regions represent the most significant growth opportunities for Chirocaine?

North America and Europe will maintain dominance due to established healthcare infrastructure. The Asia-Pacific region promises high growth, driven by increasing surgical volumes and healthcare investments.

5. What are the competitive challenges faced by Chirocaine?

Competing against well-established local anesthetics like Bupivacaine and Ropivacaine, Chirocaine must demonstrate superior safety, efficacy, and cost-effectiveness to gain market share amid generic pricing pressures.


References

  1. Grand View Research. Local Anesthetics Market Size, Share & Trends Analysis Report (2022).
  2. FDA and EMA approval documents for levobupivacaine.
  3. ClinicalTrials.gov databases listing ongoing and completed trials for levobupivacaine.
  4. Market Outlook Reports by Frost & Sullivan and IQVIA (2022–2023).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.